Target intelligence / Profile preview

Concentrative nucleoside transporter 3 (hCNT3)

Target
hCNT3
Molecular classification
Transporter, Solute carrier family (SLC) protein, Nucleoside transporter
01

Overview

Concentrative nucleoside transporter 3 (hCNT3, encoded by *SLC28A3*) is a plasma membrane protein of the solute carrier family, functioning primarily as a sodium-dependent nucleoside transporter capable of importing both physiological nucleosides and a broad range of nucleoside analog therapeutic agents—including anti-cancer and antiviral drugs—into cells[1][2][3][5][7]. hCNT3 is structurally characterized by a homo-trimeric assembly and is broadly expressed in human tissues, particularly in the kidney and epithelia[1][3][4]. Its broad substrate selectivity and pivotal transport role render it a key determinant of tissue disposition and pharmacological efficacy of nucleoside analog drugs. Genetic variants in *SLC28A3* can modulate function and expression, impacting drug response and toxicity[7].

Other names
SLC28A3CNT3solute carrier family 28 member 3
02

Mechanism of action

Facilitates sodium-dependent cellular uptake of nucleosides and nucleoside analog drugs, enabling their cytotoxic or antiviral activity by permitting intracellular accumulation[2][3][7].

03

Biological functions

Nucleoside transportCellular uptake of nucleoside analog drugsSodium-coupled substrate transportRegulation of nucleoside salvage pathway
04

Disease associations

CancerAntiviral responseDrug resistanceOther (pharmacogenomics and individual drug response variability)
05

Safety considerations

Variation/mutations in SLC28A3 can alter drug uptake, potentially leading to chemoresistance or toxicity[7].Off-target effects may arise from interference with endogenous nucleoside salvage pathways.Potential for altered pharmacokinetics of nucleoside-based drugs in individuals with SLC28A3 polymorphisms.
06

Interacting drugs

Fludarabine

5 more in the full profile.

07

Biomarkers

SLC28A3 (CNT3) expression levels serve as biomarkers for nucleoside/drug uptake capacity and potential drug response/resistance in cancer therapy[3][7].

Beyond the preview

Go deeper on Concentrative nucleoside transporter 3 (hCNT3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Concentrative nucleoside transporter 3 (hCNT3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call